Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1541546
PUBLISHER: IMARC | PRODUCT CODE: 1541546
Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2024-2032
PUBLISHED:
PAGES: 136 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global liposomal doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.
Liposomal Doxorubicin Market Trends:
The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.
Breakup by Product:
Doxil/Caelyx
Lipodox
Myocet
Others
Breakup by Application:
Leukemia
Bone Sarcoma
Breast Cancer
Endometrial Cancer
Kidney Cancer
Multiple Myeloma
Kaposi Sarcoma
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.
Key Questions Answered in This Report:
- How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global liposomal doxorubicin market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global liposomal doxorubicin market and who are the key players?
- What is the degree of competition in the industry?
Product Code: SR112024A3921
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Liposomal Doxorubicin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Doxil/Caelyx
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Lipodox
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Myocet
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Application
- 7.1 Leukemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Bone Sarcoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Breast Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Endometrial Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Kidney Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Multiple Myeloma
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Kaposi Sarcoma
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
- 7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Baxter International Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Cipla Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Johnson & Johnson
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Merck KGaA
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Sun Pharmaceutical Industries Ltd
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 TTY Biopharm Company Limited
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Zydus Cadila
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.1 Baxter International Inc.
Product Code: SR112024A3921
List of Figures
- Figure 1: Global: Liposomal Doxorubicin Market: Major Drivers and Challenges
- Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2023
- Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2023
- Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2023
- Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
- Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2023
- Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
- Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
- Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Liposomal Doxorubicin Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Liposomal Doxorubicin Market Forecast: Breakup by Product (in Million US$), 2024-2032
- Table 3: Global: Liposomal Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
- Table 4: Global: Liposomal Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 5: Global: Liposomal Doxorubicin Market: Competitive Structure
- Table 6: Global: Liposomal Doxorubicin Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.